The top ranked molecule was tafluprost (Drugbank_ID: DB08819), a prostaglandin F2α (PGF2α)-type agonist currently used as a treatment for glaucoma and ocular hypertension (Papadia et al., 2011; Klimko and Sharif, 2019), which in theory should be, a new putative multitarget ligand of NaV1.5 and TASK-1. This evidence concerns the gene SCN5A and glaucoma.